SUBSCRIBE
SUBSCRIBE
News   Policy

Astellas Pharma Inc. Sees U.S. Delay on Transplant Drug Advagraf

March 14, 2008 | 
1 min read
TOKYO (Reuters) - Japan's Astellas Pharma Inc said on Friday that U.S. authorities have requested more information on its key kidney transplant drug Advagraf, meaning it will face further delays in receiving approval there.
Regulatory Asia
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Illustration showing a downward graph trend
Regulatory
Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program
May 15, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessperson group is walking towards career success or a vacant promotion competition. isometric vector illustration.
FDA
Biotech leaders pitch Pazdur as next FDA chief
May 14, 2026
 · 
2 min read
 · 
Annalee Armstrong
Editable vector illustration of a man winning a race. Hi-res jpeg file included.
Approvals
BeOne wins mantle cell lymphoma approval, opening new therapy class
May 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessman pulling rope trying to lift up falling graph.
Complete response letters
UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged
May 13, 2026
 · 
3 min read
 · 
Annalee Armstrong